NEW YORK, June 14, 2013 /PRNewswire/ --

Today, Wall Street Reports announced new research reports highlighting Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), BioMarin Pharmaceutical Inc. (NASDAQ: BMRN), Onyx Pharmaceuticals, Inc. (NASDAQ: ONXX), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), and ImmunoGen, Inc. (NASDAQ: IMGN). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Alexion Pharmaceuticals, Inc. Research Report

On June 5, 2013, Alexion Pharmaceuticals, Inc. (Alexion) announced that the results of trials published in The New England Journal of Medicine (NEJM) showed that chronic Soliris (eculizumab) therapy is effective in the treatment of patients with atypical hemolytic uremic syndrome (aHUS), a genetic, life-long, ultra-rare disease associated with vital organ failure and premature death. According to results of two pivotal studies published in the NEJM, chronic Soliris treatment substantially inhibits systemic complement-mediated thrombotic microangiopathy (TMA), decreases the need for TMA-related intervention, and results in significant and sustained improvement in platelet count. It also increasingly improves renal function across patient groups over time, and is associated with substantial kidney recovery in patients with aHUS. Soliris was approved for the treatment of patients with aHUS in the US, Europe, and other countries based on data from the two prospective studies published in NEJM. The Full Research Report on Alexion Pharmaceuticals , Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [ http://www.wsreports.com/r/full_research_report/451f_ALXN]

--

BioMarin Pharmaceutical Inc. Research Report

On June 5, 2013, BioMarin Pharmaceutical Inc. (BioMarin) announced that it has initiated the Phase 3 program for PEG-PAL (PEGylated recombinant Phenylalanine Ammonia Lyase) for the treatment of phenylketonuria (PKU). "Adult patients with PKU and patients on the severe end of the disease spectrum still represent a very high unmet medical need. With PEG-PAL, it may be possible to provide a treatment benefit to this population," said Hank Fuchs, M.D., Chief Medical Officer of BioMarin. The Phase 3 study (165-301) is an open-label, multi-center study to assess the safety and tolerability of an induction, titration, and maintenance dose regimen of PEG-PAL self-administered by approximately 90 naive adult PKU subjects. After completion of the open label 165-301 study, subjects are expected to enroll in 165-302, a Phase 3 double-blind, placebo-controlled, randomized discontinuation study to evaluate the efficacy and safety of PEG-PAL self-administered by adults with PKU. The Full Research Report on BioMarin Pharmaceutical Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/936c_BMRN]

--

Onyx Pharmaceuticals, Inc. Research Report

On June 3, 2013, Onyx Pharmaceuticals, Inc. (Onyx) and the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center announced the formation of the Oncology Innovation Alliance (OIA). OIA is a public-private partnership focusing on the discovery and development of novel therapies and their potential role in treating various types of hematologic cancers and solid tumors. The alliance intends to transform cancer care by harnessing the expertise in fundamental science and medicine at both UCSF and Onyx to address the full continuum of that care, from prediction and diagnosis to new therapies and post-treatment monitoring, to identify opportunities to improve the patient experience and outcomes. The term of the agreement extends for three years. The Full Research Report on Onyx Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.wsreports.com/r/full_research_report/fcf8_ONXX]

--

Questcor Pharmaceuticals, Inc. Research Report

On June 10, 2013, Questcor Pharmaceuticals, Inc. (Questcor) announced the addition of Angus C. Russell, recently-retired CEO of Shire plc, to Questcor's Board of Directors. "Angus is a respected biopharmaceutical industry leader with a proven track in specialty pharmaceuticals," said Virgil D. Thompson, Chairman of Questcor's Board of Directors. "We look forward to benefitting from Angus' 32 years of experience in the specialty pharmaceutical industry as we continue to focus on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders." "The growth of scientific knowledge regarding the importance of melanocortin receptors in immunomodulation provides Questcor with a large potential growth opportunity over the next few years," Angus added. Further, on May 29, 2013, the Company's Board of Directors declared a quarterly cash dividend of $0.25 per share to shareholders of record at the close of business on July 22, 2013, payable on or about July 30, 2013. The Full Research Report on Questcor Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [ http://www.wsreports.com/r/full_research_report/ad11_QCOR]

--

ImmunoGen, Inc. Research Report

On June 3, 2013, ImmunoGen, Inc. (ImmunoGen) announced the presentation of the first clinical data with the Company's IMGN853 product candidate. The data belong to the ongoing dose-finding portion of a Phase I clinical assessment of the compound, which is a potential treatment for many ovarian, endometrial, and non-small cell lung cancers, as well as other FRalpha-overexpressing cancers. The dose-finding portion of the Phase I clinical trial is designed to establish the maximum tolerated dose of IMGN853 and to define its dose-limiting toxicity (DLT). At the time of data cutoff for presentation, 18 patients had received IMGN853 at doses ranging from 0.15 to 7 mg/kg. DLT, seen at 7 mg/kg, was reversible blurred vision with epithelial corneal changes. While the assessment is designed to evaluate the safety of IMGN853 and establish its maximum tolerated dose, evidence of clinical activity is also being identified. The Company expects to begin the disease-specific, dose-expansion phase of the trial in late 2013. The Full Research Report on ImmunoGen, Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [ http://www.wsreports.com/r/full_research_report/18c3_IMGN]

----

EDITOR NOTES:

        
        1) This is not company news. We are an independent source and our views do
          not reflect the companies mentioned.
        2) Information in this release is fact checked and produced on a best efforts
          basis and reviewed by a CFA. However, we are only human and are prone to make
          mistakes. If you notice any errors or omissions, please notify us below.
        3) This information is submitted as a net-positive to companies mentioned, to
          increase awareness for mentioned companies to our subscriber base and the investing
          public.
        4) If you wish to have your company covered in more detail by our team, or wish
          to learn more about our services, please contact us at
          pubco@EquityNewsNetwork.com.
        5) For any urgent concerns or inquires, please contact us at
          compliance@EquityNewsNetwork.com.
        6) Are you a public company? Would you like to see similar coverage on your
          company? Send us a full investors' package to research@EquityNewsNetwork.com for
          consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

SOURCE Wall Street Reports